Literature DB >> 3874064

In vivo imaging of the human thyroid with a positron camera using 124I.

P Frey, D Townsend, A Jeavons, A Donath.   

Abstract

A high-density avalanche chamber (HIDAC) positron camera was used for tomographic imaging of the human thyroid in vivo. Images were made 7 and 24 h after the oral administration of the positron-emitting radionuclide, sodium iodide 124I (with activities varying between 0.3 and 1 mCi), to patients scheduled for either partial thyroidectomy or radioiodine treatment. The results of thyroid imaging performed on 38 patients and their clinical relevance are discussed; as an illustration, three typical cases are presented. In Graves' disease, it was found that, whereas standard 131I and 124I scintigrams showed a diffuse goitre, positron images indicated a marked heterogeneity of the activity distribution, with "cold" areas in 8 out of the 11 cases studied. In conventional scintigrams, multinodular goitre showed a non-uniform radioiodine distribution, while positron images revealed considerable regional differences of activity uptake, with hot and cold areas in all of the 13 cases studied. As a consequence of the high spatial resolution of the camera [2.5 mm full width at half maximum (FWHM)], the functional volume of the thyroid may be estimated from 2 mm-thick transverse tomographic sections to within about 13%. This estimate may be compared with the measured volume after partial thyroidectomy, and in a follow-up scan, a further estimate can be made of the residual thyroid tissue remaining within the patient's body. In the case of radioiodine treatment in Graves' disease and multinodular goitre, the appropriate therapeutic dose of 131I can calculated according to the functional volume of the thyroid estimated from 124I tomographic images.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3874064     DOI: 10.1007/bf00256597

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  7 in total

1.  Planar and SPECT imaging in the era of PET and PET-CT: can it survive the test of time?

Authors:  Abass Alavi; Sandip Basu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08       Impact factor: 9.236

Review 2.  Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancer.

Authors:  Lutz S Freudenberg; Walter Jentzen; Alexander Stahl; Andreas Bockisch; Sandra J Rosenbaum-Krumme
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-12       Impact factor: 9.236

3.  Preparation and in vivo study of 124I-labelled monoclonal antibody H17E2 in a human tumour xenograft model. A prelude to positron emission tomography (PET).

Authors:  D E Snook; G Rowlinson-Busza; H L Sharma; A A Epenetos
Journal:  Br J Cancer Suppl       Date:  1990-07

4.  Value of (124)I-PET/CT in staging of patients with differentiated thyroid cancer.

Authors:  L S Freudenberg; G Antoch; W Jentzen; R Pink; J Knust; R Görges; S P Müller; A Bockisch; J F Debatin; W Brandau
Journal:  Eur Radiol       Date:  2004-06-30       Impact factor: 5.315

5.  Combined PET/CT with iodine-124 in diagnosis of spread metastatic thyroid carcinoma: a case report.

Authors:  L S Freudenberg; G Antoch; R Görges; J Knust; R Pink; W Jentzen; J F Debatin; W Brandau; A Bockisch; J Stattaus
Journal:  Eur Radiol       Date:  2003-12       Impact factor: 5.315

6.  Disseminated iodine-avid lung metastases in differentiated thyroid cancer: a challenge to 124I PET.

Authors:  Lutz S Freudenberg; Walter Jentzen; Stefan P Müller; Andreas Bockisch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-11-20       Impact factor: 10.057

7.  The diagnostic value of 124I-PET in patients with differentiated thyroid cancer.

Authors:  Ha T T Phan; Pieter L Jager; Anne M J Paans; John T M Plukker; M G G Sturkenboom; W J Sluiter; Bruce H R Wolffenbuttel; Rudi A J O Dierckx; Thera P Links
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01-04       Impact factor: 9.236

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.